Disease Detail

ID DOID:1520
Name colon carcinoma
Definition A colon cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colon cancer colon carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E RXDX-105 colon carcinoma sensitive detail...
Unknown unknown Bevacizumab + S-49076 colon carcinoma not applicable detail...
MSH6 loss N/A colon carcinoma not applicable detail...
APC inact mut FH535 colon carcinoma sensitive detail...
Unknown unknown BMS-906024 colon carcinoma not applicable detail...
TP53 loss SP600125 colon carcinoma sensitive detail...
Unknown unknown Mps-BAY1 colon carcinoma not applicable detail...
Unknown unknown Mps-BAY2a colon carcinoma not applicable detail...
Unknown unknown Mps-BAY2b colon carcinoma not applicable detail...
Unknown unknown Mps-BAY1 + Paclitaxel colon carcinoma not applicable detail...
Unknown unknown Mps-BAY2a + Paclitaxel colon carcinoma not applicable detail...
Unknown unknown Mps-BAY2b + Paclitaxel colon carcinoma not applicable detail...
TP53 loss MPI-0479605 colon carcinoma sensitive detail...
TP53 wild-type MPI-0479605 colon carcinoma sensitive detail...
TP53 wild-type RB1 wild-type R547 colon carcinoma sensitive detail...
TP53 mutant RB1 wild-type R547 colon carcinoma sensitive detail...
IDH1 R132H Talazoparib colon carcinoma sensitive detail...
IDH1 R132H Olaparib colon carcinoma sensitive detail...
Unknown unknown CFI-402257 + unspecified PD-1 antibody colon carcinoma not applicable detail...
Unknown unknown UD-017 colon carcinoma not applicable detail...
Unknown unknown Hydroxyurea + MU380 colon carcinoma not applicable detail...
Unknown unknown CA-170 colon carcinoma not applicable detail...
TP53 mutant Camptothecin + CHIR-124 colon carcinoma predicted - sensitive detail...
ALK negative CEP-28122 colon carcinoma resistant detail...
Unknown unknown Radiotherapy + XL-844 colon carcinoma not applicable detail...
CTNNB1 S45del NTRC 0066-0 colon carcinoma predicted - sensitive detail...
CTNNB1 S45del Mps-BAY2b colon carcinoma predicted - sensitive detail...
CTNNB1 S45del NMS-P715 colon carcinoma predicted - sensitive detail...
CTNNB1 S45del BAY1161909 colon carcinoma predicted - sensitive detail...
CTNNB1 S45del BAY1217389 colon carcinoma predicted - sensitive detail...
CTNNB1 S45del Mps1-IN-1 colon carcinoma predicted - sensitive detail...
CTNNB1 S45del MPI-0479605 colon carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01309126 Phase III Cetuximab Cetuximab + PGG beta-glucan Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Terminated
NCT01985763 Phase Ib/II Genistein Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Genistein in Treatment of Metastatic Colorectal Cancer Completed
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting